Kodiak Sciences Inc. is a biotechnology company focused on researching, developing, and commercializing therapeutics for retinal diseases. The company is advancing multiple product candidates, including Zenkuda™ (tarcocimab tedromer), KSI-501, and KSI-101, which target conditions such as wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Kodiak operates primarily in the ophthalmology sector, aiming to address significant unmet needs in the treatment of vision-threatening conditions.
